Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Immunotherapy of cancer

2428 - Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)

Date

10 Oct 2016

Session

Immunotherapy of cancer

Presenters

Roy Herbst

Citation

Annals of Oncology (2016) 27 (6): 1-36. 10.1093/annonc/mdw435

Authors

R.S. Herbst1, J. Martin-Liberal2, E. Calvo3, N. Isambert4, J.C. Bendell5, P. Cassier6, J.L. Perez-Gracia7, J. Yang8, J. Rege8, G. Mi9, D. Ferry8, L. Paz-Ares10

Author affiliations

  • 1 Thoracic Oncology Research Program, Yale University School of Medicine, 06520-8028 - New Haven/US
  • 2 Early Drug Development Unit (uitm), Vall d'Hebron University Hospital, Barcelona/ES
  • 3 Early Clinical Drug Development Program, START Madrid-HM CIOCC, Centro Integral Oncológico Clara Campal, Madrid/ES
  • 4 Medicine, Centre Georges François Leclerc, Dijon/FR
  • 5 Gi Oncology Research, Sarah Cannon Research Institute and Tennessee Oncology, 37203 - Nashville/US
  • 6 Clinical Research, Centre Léon Bérard and Claude Bernard University, - - Lyon/FR
  • 7 Medical Oncology, Universidad de Navarra, 31008 - Pamplona/ES
  • 8 Oncology, Eli Lilly and Company, 08807 - Bridgewater/US
  • 9 Oncology, Eli Lilly and Company, Indianapolis/US
  • 10 Medical Oncology, Virgen del Rocio University Hospital, Seville/ES
More

Resources

Abstract 2428

Background

Hallmarks of tumor growth include angiogenesis and immunosuppression. This is the first study to combine R (VEGFR2 antibody) with P (PD-1 antibody) to target both processes simultaneously. R and P have both shown clinical activity in multiple tumor types.

Methods

This ongoing phase 1a/b study (NCT02443324) enrolled pts with gastric or gastroesophageal junction (G/GEJ), NSCLC, urothelial carcinoma (UC), or biliary tract cancer (BTC) following progression on systemic therapy. The primary end point was to define safety and tolerability of adding R to P; preliminary efficacy will be examined. The DAKO PD-L1 22C3 IHC pharmDx assay was used to classify PD-L1 as strong pos (≥50%), weak pos (1-49%), or neg for NSCLC pts.

Results

As of data cut-off on 23-June-2016, 91 pts have been enrolled with G/GEJ, UC or NSCLC and 66 (73%) experienced a treatment-related AE (TRAE). Fifteen (16%) pts experienced grade 3-4 TRAEs, most commonly colitis (4%) and hypertension (4%). One treatment related death occurred in the G/GEJ cohort (pneumocystis pneumonia and pulmonary sepsis). Pts with previously treated advanced NSCLC (n = 27) received R at 10 mg/kg on Day 1 with P 200 mg on Day 1 q3W. The median age was 65, 78% were male, 96% had a history of smoking, 78% had adenocarcinoma and 15% had squamous-cell carcinoma. Sixteen (59%) pts received ≥2 and 4 (15%) pts received ≥3 prior treatment regimens for their disease. Overall, 22 (81%) pts experienced a TRAE, most commonly asthenia (19%) and hypertension (19%). Two (7%) pts experienced grade 3-4 TRAEs (adrenal insufficiency, hyponatremia, delirium, and infusion related reaction). Eight (30%) pts had an objective response (1 unconfirmed). Responses occurred in both histological subtypes and all PD-L1 groups. The disease control rate was 85%. Median time to response was 1.45mo and median duration of response has not been reached. Median PFS has not been reached (95% CI, 3.98 to NR). Median duration of treatment is 6.8mo or longer. Objective responses were still ongoing in all responders.

Conclusions

R + P generated no new safety signals and demonstrated promising clinical activity in pts with previously treated advanced NSCLC, including PD-L1 neg pts.

Clinical trial identification

NCT02443324

Legal entity responsible for the study

Eli Lilly and Company

Funding

Eli Lilly and Company

Disclosure

R.S. Herbst: funding from Merck and Lilly, and served as an advisory board member for AstraZeneca, Bristol-Myers Squibb, Genentech, Roche and Lilly. E. Calvo: Consulting-Novartis,GSK,Astellas,Roche,Lilly,Nanobiotech,Pfizer Speaker's Bureau -Novartis Research – Boehringer Ingelheim,Roche,BMS,Novartis,PsiOxus,Janssen,Eisai,Abbvie, OncoMed,Pharmamar,Puma Travel, Expenses – Lilly,PsiOxus,Novartis. P. Cassier: Grants/research - Roche/Genentech, Novartis, AstraZeneca, Celgene, Bayer, BluePrint, Amgen, Ignyta, Eli Lilly Co Honorarium - Roche, Novartis, Amgen. J.L. Perez-Gracia: Corporate Sponsored Research – Eli Lilly and Company. J. Yang, J. Rege, G. Mi, D. Ferry: Employment and stock ownership Eli Lilly and Company. L. Paz-Ares: Scientific advice - Roche, Lilly, Astra Zeneca, Merck Sharp, Boehringer Ing.,Bristol Meyers Squibb, Pfizer, Clovis Oncology, Novartis, Bayer, Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings